Skip to main content
Premium Trial:

Request an Annual Quote

Reagents Applera, Promega Settle; Details Remain Confidential


Facing a fast-approaching trial thanks to Wisconsin’s accelerated court system, the so-called “rocket docket,” Applera and Promega have settled their reagent-based patent infringement suits against each other.

According to Don Best, attorney for Promega, the settlement was entered and the case dismissed by the end of October. One of the patents at issue was the one of the three automated DNA sequencer patents that has been charged as illegitimate in an unrelated MJ Research suit against Applera, which was reason enough for the industry to watch the outcome of the Promega suit with interest.

The settlement came at the eleventh hour for both sides. “When you’re a month away [from trial], it gets pretty intense,” Best says. “Both parties end up doing a ton of work, as you might expect, to get a case of this magnitude and complexity … ready for trial.”

Though the confidentiality details of the settlement have not yet been determined, each side is acting as though all aspects of the agreement are top-secret, Best says. No doubt their silence will simply add fuel to the rumors that will certainly be making the industry rounds on who the “victor” was.


The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.